Search

Your search for "NNVC" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma

September 26, 2024

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) […]

InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Releases Q2 Financial Report

May 15, 2024

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, has filed on its second-quarter 2024 financial results for the period ending March 31, 2024; the company filed the report with the U.S. Securities and Exchange Commission on May 14, 2024. Notable numbers from the report include cash and cash equivalent totaling $3.51 million, […]

InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports ‘Extremely Significant Results in HV-387 Animal Study Treating RSV

May 14, 2024

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the antiviral activity of its lead candidate, NV-387, against RSV/A2 is “strong enough to have resulted in full survival of lethally infected animals.” According to the announcement, the company conducted a study that involved extended dosing of NV-387 given orally; those […]

InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Exec Participating at Upcoming EF Hutton Global Conference

May 10, 2024

NanoViricides (NYSE American: NNVC) president and executive chair Anil R. Diwan, PhD, will be attending this month’s EF Hutton Annual Global Conference; the event is slated for May 15, 2024, in New York City. NanoViricides is a global leader in broad-spectrum antiviral nanomedicines. The conference provides an opportunity for key executives from public and private […]

InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Lead Drug Candidate Indicates Strong Orthopoxvirus Activity

May 8, 2024

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that, in a lethal animal model, its lead drug candidate, NV-387, showed ultra-broad antiviral activity, including activity against the orthopoxvirus family, including smallpox and mpox. According to the announcement, in the model of lung infection by Ectromelia virus, oral dosing with NV-387 […]

InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Reports that NV-387 Shows Strong Activity Against Influenza A

May 6, 2024

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the ultra-broad antiviral activity spectrum of NV-387 includes influenza A viruses, possibly including bird flu H5N1 virus as well. According to the announcement, the company performed a lethal animal model of lung infection by influenza A/H3N2 virus that indicated NV-387 showed […]

InvestorNewsBreaks

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference

May 4, 2023

NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; […]

Press Releases

NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City

May 4, 2023

SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) — (via IBN) — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which […]

News Articles

NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference

May 3, 2023

NanoViricides (NYSE American: NNVC) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 for the treatment of COVID caused by SARS-CoV-2 coronavirus. NV-CoV-2 is […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).